by FAYYADH JAAFAR / pic by TMR FILE
VACCINE maker Moderna announced plans to establish new subsidiaries in Malaysia, Singapore, Taiwan and Hong Kong.
This network expansion builds on Moderna’s existing presence in the region, with offices in Japan, South Korea, and Australia, and demonstrates Moderna’s continued commitment to the Asia-Pacific region as an essential part of Moderna’s long-term strategy and commercial vision, Moderna said in a statement today.
Stéphane Bancel, Chief Executive Officer of Moderna said Malaysia is a growing player in the pharmaceutical and biotech industry, and Moderna looks forward to exploring opportunities for local collaboration as the company expands its footprint in the Asia-Pacific region.
“I am excited to build strong teams that can deliver on the potential this region and our mRNA platform has to offer.”
“Moderna’s plan to establish a local subsidiary reflects the Company’s confidence in the current growth trajectory of Malaysia’s pharmaceutical and healthcare industries. Moderna is further encouraged by the local government’s commitment to biotech research and development,” he added.
Moderna is actively recruiting a team to build a strong Moderna presence in the market as the Company’s mRNA therapeutics pipeline grows.
Moderna’s broader pipeline currently includes 40 development programs, of which 25 are in clinical trials.
The Company continues to update its COVID-19 strategy to address variants of concern such as Omicron and pioneer new vaccines and therapeutics for a range of diseases and conditions.
It is also developing mRNA medicines to potentially prevent and treat diseases with significant unmet needs across infectious diseases, immuno-oncology, rare and ultra-rare diseases, and autoimmune diseases.
Moderna currently has a presence in twelve markets globally.
Regulators have approved Moderna’s COVID-19 vaccine in more than 70 markets, including at least 19 in the Asia-Pacific region.
In August 2021, the Malaysia Ministry of Health granted Moderna’s COVID-19 vaccine conditional approval for emergency use.